Our research is focused on investigating the underlying mechanisms of disease using molecularly targeted imaging agents. We develop and utilize methodologies for imaging diseases such as multiple myeloma with high sensitivity and specificity. Our imaging probes are based on peptides, nanoparticles and antibodies; which combined with nuclear, optical, and magnetic resonance imaging platforms confer information in nano-, meso- and micro- scale. Our interdisciplinary group is involved in various aspects of bench to bedside translation. We are fundamentally dedicated to Education, Diversity, Discovery, Innovation and Clinical Translation.
From the abstract: In the current era of precision medicine, there is renewed interest in radiopharmaceutical therapy and theranostics. The approval of somatostatin receceptor directed therapy and norepinephrine transporter targeted 131I-MIBG therapies by the FDA and the rapid progress of highly promising beta and alpha emitter tagged PSMA directed therapy of prostate cancer have stimulated clinically […]
Dr. Shokeen recently received an award from Siteman Cancer Center as a part of a $2.1 million dollar grant for cancer research. Along with Gregory Lanza, PhD, Dr. Shokeen will lead a research team to develop proof-of-concept evidence related to the therapeutic response and effectiveness of a new targeted combination nanotherapy for patients with multiple […]
The Academy of Educators at Washington University School of Medicine is an institutional collaboration of educators who together will foster a culture of educational excellence and an institutionally valued community of leaders in health science education. Read more here.
From the abstract: Cluster of differentiation 38 (CD38) is a promising therapeutic target in multiple myeloma (MM) patients and has resulted in the development of several CD38 immunotherapies. Current methods to evaluate CD38 expression in the preclinical setting include ex vivo flow cytometry and immunohistochemistry, which can be cumbersome and do not give whole-body information. In vivo imaging technologies […]
Dr. Shokeen received a 5-year R01 grant funded by the National Institutes of Health/National Cancer Institute (06/01/2020 – 05/31/2025)! This funding will support the project titled, “Exploring CD38 molecular biology and imaging in multiple myeloma pathogenesis.” In this proposal, Dr. Shokeen and her team will develop new CD38 targeted peptide-based PET imaging probes for multiple […]